JP2007501859A - γ−セクレターゼ阻害剤としての架橋ｎ−アリールスルホニルピペリジン - Google Patents

γ−セクレターゼ阻害剤としての架橋ｎ−アリールスルホニルピペリジン Download PDF

Info

Publication number
JP2007501859A
JP2007501859A JP2006532943A JP2006532943A JP2007501859A JP 2007501859 A JP2007501859 A JP 2007501859A JP 2006532943 A JP2006532943 A JP 2006532943A JP 2006532943 A JP2006532943 A JP 2006532943A JP 2007501859 A JP2007501859 A JP 2007501859A
Authority
JP
Japan
Prior art keywords
alkyl
compound
aryl
cycloalkyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006532943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501859A5 (https=
Inventor
フーベルト ジョシェン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2007501859A publication Critical patent/JP2007501859A/ja
Publication of JP2007501859A5 publication Critical patent/JP2007501859A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
JP2006532943A 2003-05-13 2004-05-11 γ−セクレターゼ阻害剤としての架橋ｎ−アリールスルホニルピペリジン Pending JP2007501859A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47014603P 2003-05-13 2003-05-13
PCT/US2004/014671 WO2004101562A2 (en) 2003-05-13 2004-05-11 Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors

Publications (2)

Publication Number Publication Date
JP2007501859A true JP2007501859A (ja) 2007-02-01
JP2007501859A5 JP2007501859A5 (https=) 2007-06-28

Family

ID=33452372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006532943A Pending JP2007501859A (ja) 2003-05-13 2004-05-11 γ−セクレターゼ阻害剤としての架橋ｎ−アリールスルホニルピペリジン

Country Status (14)

Country Link
US (1) US7368457B2 (https=)
EP (1) EP1641801B9 (https=)
JP (1) JP2007501859A (https=)
CN (1) CN1820010A (https=)
AR (1) AR044294A1 (https=)
AT (1) ATE401328T1 (https=)
CA (1) CA2525124A1 (https=)
CL (1) CL2004001011A1 (https=)
DE (1) DE602004015110D1 (https=)
ES (1) ES2308206T3 (https=)
MX (1) MXPA05012268A (https=)
PE (1) PE20050555A1 (https=)
TW (1) TW200510405A (https=)
WO (1) WO2004101562A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528865A (ja) * 2009-06-02 2012-11-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１βヒドロキシステロイドデヒドロゲナーゼ１のカルバマート及びウレアインヒビター

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
PE20060481A1 (es) * 2004-06-30 2006-06-19 Schering Corp N-arilsulfonilaminas heterociclicas sustituidas como inhibidores de gamma-secretasas
BRPI0614944A2 (pt) * 2005-08-19 2011-04-26 Elan Pharm Inc inibidores sulfonamido n-bicìclicos ponte de gama-secretase
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
WO2013096744A1 (en) 2011-12-21 2013-06-27 Novira Therapeutics, Inc. Hepatitis b antiviral agents
EA038942B1 (ru) 2012-08-28 2021-11-12 Янссен Сайенсиз Айрлэнд Юси Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
EA035500B1 (ru) 2013-05-17 2020-06-25 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b
TWI651300B (zh) 2013-05-17 2019-02-21 健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
WO2015118057A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015131773A1 (zh) * 2014-03-06 2015-09-11 上海海雁医药科技有限公司 作为食欲素受体拮抗剂的哌啶衍生物
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
HK1259410A1 (zh) 2015-09-29 2019-11-29 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076440A2 (en) * 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5006015838, ＭＯＭＯＳＥ， ＴＡＫＥＦＵＭＩ, ＨＥＴＥＲＯＣＹＣＬＥＳ, 1977, Ｖ６ Ｎ４, Ｐ４６９−４７４ *
JPN6010066104, Ｗａｎｇ， Ｈｕｉｎｉｎｇ ｅｔ ａｌ．， Ｆｅｎｘｉ Ｈｕａｘｕｅ （１９９１）， １９（１１）， １３０８−１３１０ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528865A (ja) * 2009-06-02 2012-11-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１βヒドロキシステロイドデヒドロゲナーゼ１のカルバマート及びウレアインヒビター
US9163012B2 (en) 2009-06-02 2015-10-20 Vitae Pharmaceuticals, Inc. Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1

Also Published As

Publication number Publication date
CN1820010A (zh) 2006-08-16
MXPA05012268A (es) 2006-02-10
DE602004015110D1 (de) 2008-08-28
AR044294A1 (es) 2005-09-07
US20040229902A1 (en) 2004-11-18
WO2004101562A3 (en) 2005-02-10
CL2004001011A1 (es) 2005-03-18
EP1641801B1 (en) 2008-07-16
ES2308206T3 (es) 2008-12-01
EP1641801B9 (en) 2009-02-25
US7368457B2 (en) 2008-05-06
TW200510405A (en) 2005-03-16
EP1641801A2 (en) 2006-04-05
CA2525124A1 (en) 2004-11-25
WO2004101562A2 (en) 2004-11-25
PE20050555A1 (es) 2005-07-19
ATE401328T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
JP2007501859A (ja) γ−セクレターゼ阻害剤としての架橋ｎ−アリールスルホニルピペリジン
JP4335532B2 (ja) Ｍｃｈアンタゴニストおよび肥満治療でのそれらの使用
CN107735087B (zh) 组蛋白脱乙酰酶抑制剂及其组合物和使用方法
JP4643141B2 (ja) 肥満治療用のｍｃｈアンタゴニスト
US20040171614A1 (en) Novel gamma secretase inhibitors
JP2005510563A (ja) 肥満およびｃｎｓ障害の処置のためのピペリジン系ｍｃｈアンタゴニスト
KR20030093248A (ko) 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제
TW200948364A (en) Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
JP4498133B2 (ja) 新規神経ペプチドｙｙ５レセプターアンタゴニスト
JP5204227B2 (ja) ベンゼンスルホニル−クロマン、チオクロマン、テトラヒドロナフタレン、および関連するガンマセクレターゼインヒビター
AU2022255486A1 (en) Nek7 inhibitors
JP2007531742A (ja) 新規のγセクレターゼインヒビター
CN101602741A (zh) 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺
EA036965B1 (ru) Ингибиторы деацетилаз гистонов и композиции и способы их применения
US20010041711A1 (en) Triazospiro compounds having nociceptin receptor affinity
WO2023084206A1 (en) N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as cd38 inhibitors
JP2007535549A (ja) 神経ペプチドレセプターモジュレーター
US10144732B2 (en) ATX modulating agents
US20050085506A1 (en) Novel gamma secretase inhibitors
TW201136588A (en) Tropinone benzylamines as beta-tryptase inhibitors
EP1773822B1 (en) Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
HK1097263B (en) Fused ring nk1 antagonists
HK1097263A1 (en) Fused ring nk1 antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110427